Abstract
Introduction
Today' s biotech industry is maturing and must now change the way it operates.
The industry is facing signifi cant challenges from operational, business,
clinical development, and market risks. Business fundamentals, which many
biotech companies have had the luxury to ignore, are now emerging as critical
elements for sustainability and survival.
Get the Answers You Need to Shape Your Strategy
- Today' s biotech market is increasingly crowded and competitive. What can
companies do to differentiate their products? What business fundamentals do
they need to understand in order to plan a successful market strategy for
their new products?
- Many successful biotech companies are surrendering their independence and
merging with larger entities. What made these companies decide to give up
their independence? Why have so many of them struggled even after launching
blockbuster drugs?
- In the rush to develop a marketed product, many biotech companies are defi
cit spending. How do some companies manage to make defi cit spending pay off?
What makes others eventually collapse?
- Many biotechs have licensed away so many of the rights to their fi rst
products that they do not reap substantial fi nancial rewards once the
products launch. Which companies have made this mistake? Why did they make
deals that left them fi nancially vulnerable?
Scope
- Challenges facing the industry: operational, business, clinical
development, and market risks.
- Business fundamentals: essential information biotechs need to run their
business in today' s market.
- Defi cit spending: case studies of how several biotechs handled defi cit
spending.
- Competing against crowded pipelines: effective strategies, case studies.
- Projections for the future: our projections on what the future holds for
the biotech industry and its synergistic relationship with the pharmaceutical
industry.
| 
View Cart
